SB623 Program for Retinal Degenerative Diseases, Spinal Cord Injury and Parkinson’s Disease
First written in FY2017. 2 of 5 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「The company has now begun nonclinical studies under a co-development framework with Ocumension (Hong Kong) Limited and is working to obtain the data required to initiate clinical trials.」
Under the co-development arrangement with Ocumension, the company continues nonclinical studies and data collection toward initiating clinical trials for the SB623 retinal disease program. - FY2022AdvancedAnnual report
「The company has now begun nonclinical studies under a co-development framework with Ocumension (Hong Kong) Limited and is working to obtain the data required to initiate clinical trials.」
The SB623 retinal disease program has begun nonclinical studies under the framework with Ocumension and has progressed to the data-gathering stage for initiating clinical trials. - FY2020AdvancedAnnual report
「For retinal disease indications, while pursuing in-house development through the early clinical trial stage and licensing out to pharmaceutical companies, we entered into an agreement with OCUMENSION (HONG KONG) LIMITED in March 2020 for joint development in Greater China, including mainland China, Hong Kong, Macau, and Taiwan, targeting retinitis pigmentosa, age-related macular degeneration (dry type), and other conditions as indications.」
In addition to pursuing early-stage development of the retinal disease program in-house, the company has secured a co-development partner in Greater China. - FY2019RestatedAnnual report
「The programs targeting retinal degenerative diseases, spinal cord injury, and Parkinson’s disease are at the nonclinical testing stage, and we will continue preparing to initiate Phase 1 clinical trials.」
The SB623 programs for retinal degenerative diseases, spinal cord injury, and Parkinson’s disease are at the nonclinical stage, and preparations to initiate Phase 1 trials are continuing. - FY2017First statedAnnual report
「The programs targeting retinal degenerative diseases, spinal cord injury, and Parkinson’s disease are currently at the nonclinical testing stage, and we will continue preparing to initiate Phase 1 clinical trials.」
The SB623 programs in 3 disease areas are at the nonclinical stage, and preparations are under way to initiate Phase 1 clinical trials.